CD30-targeted immunotherapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD30-targeted immunotherapy, covering 2026-01-02 to 2026-01-02. Get the full timeline:
Most recent: Clinical Trial Update: GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma [Phase 1, Phase 2]